Skip to content

Advertisement

  • Erratum
  • Open Access

Erratum to: Vascular endothelial growth factor-A (VEGF-A) and chemokine ligand-2 (CCL2) in amyotrophic lateral sclerosis (ALS) patients

  • 1,
  • 1,
  • 2 and
  • 1Email author
Contributed equally
Journal of Neuroinflammation20118:97

https://doi.org/10.1186/1742-2094-8-97

  • Received: 8 August 2011
  • Accepted: 11 August 2011
  • Published:

The original article was published in Journal of Neuroinflammation 2011 8:47

Abstract

Correction to Gupta P K, Prabhakar S, Sharma S, Anand A. Vascular endothelial growth factor-A (VEGF-A) and chemokine ligand-2 (CCL2) in amyotrophic lateral sclerosis (ALS) patients. Journal of Neuroinflammation 8:47.

Correction

The authors observe that, in Table two of our study [1], crude ORs and adjusted ORs for serum VEGFA were also repeated for CSF VEGFA, however, these values for CSF VEGFA are different from serum VEGFA. Correct OR values of CSF VEGFA are given below.

Smoking: [crude OR(95% CI) = 1.7 (0.3-9.1), p = 0.4; adj OR (95% CI) = 0.6 (0.08-4.4), p = 0.6].

Alcohol consumption: [crude OR(95% CI) = 0.6 (0.1-2.2), p = 0.4; adj OR (95% CI) = 0.8 (0.1-4.4), p = 0.8].

Meat consumption: [crude OR(95% CI) = 2.2 (0.6-7.7), p = 0.2; adj OR (95% CI) = 2.1 (0.5-7.7), p = 0.2].

Notes

Authors’ Affiliations

(1)
Department of Neurology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh-160012, India
(2)
Department of Statistics, Panjab University, Chandigarh-160012, India

References

  1. Gupta PK, Prabhakar S, Sharma S, Anand A: Vascular endothelial growth factor-A (VEGF-A) and chemokine ligand-2 (CCL2) in amyotrophic lateral sclerosis (ALS) patients. J Neuroinflammation. 8: 47-10.1186/1742-2094-8-47.Google Scholar

Copyright

Advertisement